Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rafael Costa Lessa"'
Autor:
Vladmir Cláudio Cordeiro de Lima, Rafael Costa Lessa, José Augusto Rinck, Sandro José Martins, Marcello Ferretti Fanelli, Augusto Akikubo Rodrigues Pereira, Fernando Vidigal de Pádua, Flavio Augusto Ismael Pinto, Debora de Melo Gagliato, Geraldine Eltz Lima, Marcelo Rocha Cruz, José Rodrigues Pereira, Marclesson S. Alves, Ulisses Ribaldo Nicolau, Paulo Henrique Aires Freitas, Elizabeth Santana dos Santos, Aldo Lourenço Abbade Dettino, Newton Augusto Ferreira Rodrigues
Publikováno v:
Web of Science
e18078 Background: First-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) with platinum-based doublets, including pemetrexed (P) or bevacizumab (B), has achieved more than 12 months of survival. At the moment, there are no ph
Autor:
José Rodrigues Pereira, José Augusto Rinck, Elizabeth Santana dos Santos, C. E. P. Souza, Aldo Lourenço Abbade Dettino, Ludmilla Thomé Domingos Chinen, V. C. C. de Lima, M. F. Fanelli, Ulisses Ribaldo Nicolau, Rafael Costa Lessa, Debora de Melo Gagliato, Marcelo Rocha Cruz, Augusto Akikubo Rodrigues Pereira, Flavio Augusto Ismael Pinto
Publikováno v:
Journal of Clinical Oncology. 29:e18067-e18067
e18067 Background: The combination of pemetrexed plus cisplatin (PC) was recently approved in the initial treatment of advanced stage non-small cell lung cancer (NSCLC). Studies reported comparable...
Autor:
Rafael Costa Lessa, Rafael Malagoli Rocha, Vladmir Cláudio Cordeiro de Lima, Marcello Ferretti Fanelli, Alexandre Andre Balieiro Anastacio da Costa, Felipe D'Almeida Costa, Carlos Eduardo Pires Sousa, Stephania M. Bezerra, Carlos Frederico Lopes Benevides, Paulo Henrique Aires Freitas, Newton Augusto Ferreira Rodrigues, Elizabeth Santana dos Santos, Fernando Vidigal Padua, Debora de Melo Gagliato, Geraldine Eltz Lima, Augusto Akikubo Rodrigues Pereira, Flavio Augusto Ismael Pinto
Publikováno v:
Web of Science
643 Background: Factors predictive of response to anthracyclines can help selecting patients who really benefit from its use. TOP2A (a target of anthracyclines) and HER2 genes are both amplified in 40% of breast cancers. Data from literature are conf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c101f395e409ea9cd1321899ed918755
https://publons.com/wos-op/publon/17669002/
https://publons.com/wos-op/publon/17669002/